What is Amyris?
Amyris operates as an integrated renewable products company, leveraging advanced bioscience to transform plant sugars into high-performance hydrocarbon molecules. By bridging the gap between laboratory-scale innovation and industrial-scale production, the company provides sustainable alternatives for industries ranging from cosmetics and fragrances to nutrition and health. Headquartered in Emeryville, California, with a significant operational footprint in Brazil, Amyris utilizes its proprietary fermentation technology to optimize the production of specialty ingredients. This unique market position allows the firm to address the growing global demand for sustainable consumer products while maintaining a competitive edge in the rapidly evolving synthetic biology landscape.
How much funding has Amyris raised?
Amyris has raised a total of $775.6M across 14 funding rounds:
Debt
$21.7M
Debt
$57.6M
Multiple Rounds
$59.5M
Debt
$19.1M
Multiple Rounds
$317M
Debt
$80M
Debt
$50M
Debt (2014): $21.7M, investors not publicly disclosed
Debt (2015): $57.6M, investors not publicly disclosed
Debt (2016): $20M, investors not publicly disclosed
Debt (2016): $6M, investors not publicly disclosed
Debt (2016): $8.5M, investors not publicly disclosed
Debt (2016): $25M, investors not publicly disclosed
Debt (2017): $19.1M, investors not publicly disclosed
Private Equity (2020): $112M backed by Foris Ventures
Debt (2020): $5M with participation from PPP
Share Placement (2020): $200M, investors not publicly disclosed
Debt (2022): $80M supported by Foris Ventures
Debt (2023): $50M, investors not publicly disclosed
Key Investors in Amyris
Foris Ventures
A private investment firm focused on supporting high-growth companies in the life sciences and technology sectors.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the funding round to support long-term enterprise development.
What's next for Amyris?
Looking ahead, the strategic deployment of the $50M will likely focus on optimizing production efficiencies and expanding the company's portfolio of consumer-facing brands. As Amyris transitions into a more mature phase of its lifecycle, the focus shifts toward achieving sustainable profitability through operational excellence and market penetration. The company is well-positioned to capitalize on the increasing corporate emphasis on ESG-compliant supply chains, utilizing its bioscience platform to disrupt traditional chemical manufacturing. Future growth will depend on the successful scaling of its fermentation facilities and the continued adoption of its specialty ingredients by global consumer goods partners, ensuring that the firm remains at the forefront of the bio-economy.
See full Amyris company page
